Genes News and Research

RSS

Clovis Oncology reports net loss of $30.7 million for first quarter 2014

Clovis Oncology, Inc. reported financial results for its first quarter ended March 31, 2014, and provided an update on the Company's clinical development programs for the rest of 2014.

9 May 2014

New study associates sex difference in brain with MS

A newly identified difference between the brains of women and men with multiple sclerosis (MS) may help explain why so many more women than men get the disease, researchers at Washington University School of Medicine in St. Louis report.

9 May 2014

Dyadic International's total revenue for Q1 2014 up 20%

Dyadic International, Inc., a global biotechnology company focused on the discovery, development, manufacture and sale of enzymes and others proteins for the bioenergy, bio-based chemicals, biopharmaceutical and industrial enzyme industries, today announced financial results for the first quarter ended March 31, 2014.

8 May 2014

Genetic changes linked to altered default mode network in psychosis

Researchers have identified biological processes likely to underlie altered activity in the resting-state default mode network in patients with psychosis.

8 May 2014

Leica and Affymetrix launch fully automated RNA in situ hybridization assays

Affymetrix, Inc. (NASDAQ:AFFX) and Leica Biosystems announce the launch of Affymetrix' fully automated RNA in situ hybridization assays ViewRNATM eZ Assays on the Leica BOND RX staining platform.

8 May 2014

First international molecular screening program at IMPAKT for metastatic breast cancer

While research has made great strides in recent decades to improve and significantly extend the lives of patients with early breast cancer, the needs of patients with advanced or metastatic disease have largely been ignored.

8 May 2014

Children's Hospital Los Angeles receives $3M from Simms/Mann Family Foundation

The Simms/Mann Family Foundation has made a $3 million gift to Children's Hospital Los Angeles to fund an endowed chair for the director of the Developmental Neurogenetics program within CHLA's Institute for the Developing Mind.

8 May 2014

Power of GWAS to detect human disease can be increased using statistical testing

The power of genome-wide association studies (GWAS) to detect genetic influences on human disease can be substantially increased using a statistical testing framework reported in the May issue of the journal GENETICS.

8 May 2014

FDA-cleared BD MAX Enteric Bacterial Panel now available to detect bacterial pathogens

BD Diagnostics, a segment of leading global medical technology company BD (Becton, Dickinson and Company), announced today the availability of the FDA-cleared BD MAX Enteric Bacterial Panel for use on the BD MAX System.

From BD (Becton, Dickinson and Company) 7 May 2014

Molecular subtyping provides insights into how to treat breast cancer

New evidence showing that the MammaPrint® and BluePrint® tests provide insights into how to treat breast cancer was presented at the annual conference of the American Society of Breast Surgeons (ASBrS).

7 May 2014

TGen/George Mason create strategic research alliance to benefit patients with cancer, life-threatening illnesses

The Translational Genomics Research Institute (TGen) and George Mason University today announced the creation of a strategic research alliance to benefit patients with cancer and other life-threatening illnesses.

7 May 2014

New research focuses on using wheat fiber to lower cholesterol and prevent development of heart disease

The saying, "we are what we eat," has never been more true. Nutritionists increasingly emphasize that the nutrients in the foods we consume can potentially create health and reduce disease.

7 May 2014

NanoString receives license from Health Canada to market Prosigna Breast Cancer Prognostic Gene Signature Assay

NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, today announced that it has received a Class III Medical Device License from Health Canada, clearing the company to market its Prosigna Breast Cancer Prognostic Gene Signature Assay for assessing a woman's 10-year risk of distant recurrence and accurately identifying the intrinsic biologic subtype of the tumor.

From NanoString Technologies 7 May 2014

Rice University researchers find new possibilities for benign, 'tunable' virus

Rice University scientists have designed a tunable virus that works like a safe deposit box. It takes two keys to open it and release its therapeutic cargo.

7 May 2014

Protein molecule seems to slow progression of deadly lung disease

Researchers at the University of Illinois at Chicago College of Medicine have discovered a protein molecule that seems to slow the progression of pulmonary fibrosis, a progressive lung disease that is often fatal three to five years after diagnosis.

7 May 2014

Novel bioinformatics approach suggests antimicrobial drug may help in treating advanced kidney cancer

Developing and testing a new anti-cancer drug can cost billions of dollars and take many years of research.

6 May 2014

FDA approves Alexion’s Soliris drug for treatment of atypical hemolytic uremic syndrome

Alexion Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's supplemental Biologics License Application (sBLA) providing regular approval for Soliris® (eculizumab) for the treatment of adult and pediatric patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA).

6 May 2014

BeiGene receives $5M from Merck to develop BGB-283 BRAF inhibitor

BeiGene (Beijing), Co., Ltd., an innovative oncology company focused on developing targeted and immune-oncology therapeutics, today announced the achievement of a clinical milestone in the company's collaboration with Merck Serono, the biopharmaceutical division of Merck, Darmstadt, Germany, for BGB-283, a second-generation BRAF inhibitor candidate currently in Phase 1 development.

6 May 2014

BrightFocus Foundation honors 5 outstanding scientists in fields of macular degeneration, glaucoma

The BrightFocus Foundation today honored five outstanding scientists in the fields of macular degeneration and glaucoma, presenting them with named research awards at an event during the annual meeting of the Association for Research in Vision and Ophthalmology.

6 May 2014

Environmental factors equally as important as genes in understanding causes of autism

Environmental factors are more important than previously thought in understanding the causes of autism, and equally as important as genes, according to the largest study to date to look at how autism runs in families.

5 May 2014

Genes News and Research

Clovis Oncology reports net loss of $30.7 million for first quarter 2014

New study associates sex difference in brain with MS

Dyadic International's total revenue for Q1 2014 up 20%

Genetic changes linked to altered default mode network in psychosis

Leica and Affymetrix launch fully automated RNA in situ hybridization assays

First international molecular screening program at IMPAKT for metastatic breast cancer

Children's Hospital Los Angeles receives $3M from Simms/Mann Family Foundation

Power of GWAS to detect human disease can be increased using statistical testing

FDA-cleared BD MAX Enteric Bacterial Panel now available to detect bacterial pathogens

Molecular subtyping provides insights into how to treat breast cancer

TGen/George Mason create strategic research alliance to benefit patients with cancer, life-threatening illnesses

New research focuses on using wheat fiber to lower cholesterol and prevent development of heart disease

NanoString receives license from Health Canada to market Prosigna Breast Cancer Prognostic Gene Signature Assay

Rice University researchers find new possibilities for benign, 'tunable' virus

Protein molecule seems to slow progression of deadly lung disease

Novel bioinformatics approach suggests antimicrobial drug may help in treating advanced kidney cancer

FDA approves Alexion’s Soliris drug for treatment of atypical hemolytic uremic syndrome

BeiGene receives $5M from Merck to develop BGB-283 BRAF inhibitor

BrightFocus Foundation honors 5 outstanding scientists in fields of macular degeneration, glaucoma

Environmental factors equally as important as genes in understanding causes of autism

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics